Vectura Group PLC (LON:VEC) was up 11.8% during mid-day trading on Thursday . The company traded as high as GBX 80.32 ($1.05) and last traded at GBX 79.85 ($1.04). Approximately 1,603,198 shares were traded during trading, a decline of 65% from the average daily volume of 4,610,000 shares. The stock had previously closed at GBX 71.40 ($0.93).
A number of equities research analysts recently issued reports on VEC shares. Shore Capital decreased their price target on shares of Vectura Group from GBX 105 ($1.37) to GBX 78 ($1.02) and set a “hold” rating on the stock in a research note on Monday, July 16th. Peel Hunt reaffirmed a “hold” rating on shares of Vectura Group in a research note on Wednesday, August 1st. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a GBX 140 ($1.83) price target on shares of Vectura Group in a research note on Tuesday, August 21st. Numis Securities reaffirmed a “buy” rating on shares of Vectura Group in a research note on Thursday, August 23rd. Finally, Citigroup reaffirmed a “buy” rating and set a GBX 155 ($2.03) price target on shares of Vectura Group in a research note on Monday, September 10th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of GBX 124.88 ($1.63).
ILLEGAL ACTIVITY NOTICE: “Vectura Group (VEC) Trading Up 11.8%” was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/11/10/vectura-group-vec-trading-up-11-8.html.
About Vectura Group (LON:VEC)
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.